Adage Capital Partners Gp, L.L.C. Chinook Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $29.3 Million - $60.6 Million	-1,569,890 Reduced 92.13%	134,110 $5.15 Million
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $19 Million - $23.7 Million	883,822 Added 107.76%	1,704,000 $39.4 Million
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $13.4 Million - $19.7 Million	720,178 Added 720.18%	820,178 $21.5 Million
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $875,500 - $1.17 Million	-50,000 Reduced 33.33%	100,000 $1.97 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $1.89 Million - $2.82 Million	150,000 New	150,000 $2.62 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.